Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Sitagliptin & metformin
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Apo-Sitagliptin/Metformin XR · DIN 02506270 · 50 mg & 500 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin/Metformin XR · DIN 02506270
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN/METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin/Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506270)
Source record
DIN 02506270: Apo-Sitagliptin/Metformin XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id APX
Source form: ER Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8893; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506270
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99561
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Janumet XR · DIN 02416786 · $0.8893
Sandoz Sitagliptin-Metformin XR · DIN 02529106 · $0.8893
Shortage status: active shortage (reported September 1, 2026, estimated to end October 16, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506270
Shortage record checked October 6, 2026
Apo-Sitagliptin/Metformin XR · DIN 02506289 · 50 mg & 1000 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin/Metformin XR · DIN 02506289
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN/METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin/Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506289)
Source record
DIN 02506289: Apo-Sitagliptin/Metformin XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id APX
Source form: ER Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8893; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506289
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99562
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Janumet XR · DIN 02416794 · $0.8893
Sandoz Sitagliptin-Metformin XR · DIN 02529114 · $0.8893
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506289
Shortage record checked October 6, 2026
Janumet XR · DIN 02416786 · 50 mg & 500 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet XR · DIN 02416786
Manufacturer: Merck Canada Inc.; listing date 2016-12-22
Health Canada: Marketed since 2015-01-13 · brand JANUMET XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416786)
Source record
DIN 02416786: Janumet XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id MEK
Source form: ER Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.8496; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416786
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90139
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506270 · $0.8893
Sandoz Sitagliptin-Metformin XR · DIN 02529106 · $0.8893
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416786
Shortage record checked October 6, 2026
Janumet XR · DIN 02416794 · 50 mg & 1000 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet XR · DIN 02416794
Manufacturer: Merck Canada Inc.; listing date 2014-10-29
Health Canada: Marketed since 2014-01-15 · brand JANUMET XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416794)
Source record
DIN 02416794: Janumet XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id MEK
Source form: ER Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.8496; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416794
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90140
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506289 · $0.8893
Sandoz Sitagliptin-Metformin XR · DIN 02529114 · $0.8893
Shortage status: resolved shortage (ended September 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02416794
Shortage record checked October 6, 2026
Sandoz Sitagliptin-Metformin XR · DIN 02529106 · 50 mg & 500 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Sitagliptin-Metformin XR · DIN 02529106
Manufacturer: Sandoz Canada Inc.; listing date 2023-04-28
Health Canada: Marketed since 2023-03-22 · brand SANDOZ SITAGLIPTIN-METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Sitagliptin-Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529106)
Source record
DIN 02529106: Sandoz Sitagliptin-Metformin XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id SDZ
Source form: ER Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8893; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529106
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101829
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506270 · $0.8893
Janumet XR · DIN 02416786 · $0.8893
Shortage status: resolved shortage (ended October 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529106
Shortage record checked October 6, 2026
Sandoz Sitagliptin-Metformin XR · DIN 02529114 · 50 mg & 1000 mg · extended release tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Sitagliptin-Metformin XR · DIN 02529114
Manufacturer: Sandoz Canada Inc.; listing date 2023-04-28
Health Canada: Marketed since 2023-03-22 · brand SANDOZ SITAGLIPTIN-METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Sitagliptin-Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529114)
Source record
DIN 02529114: Sandoz Sitagliptin-Metformin XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id SDZ
Source form: ER Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.8893; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529114
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101830
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506289 · $0.8893
Janumet XR · DIN 02416794 · $0.8893
Shortage status: resolved shortage (ended December 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529114
Shortage record checked October 6, 2026
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509415)
Source record
DIN 02509415: Apo-Sitagliptin Malate/Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509415
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99871
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446
Janumet · DIN 02333856 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: active shortage (reported October 8, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02509415
Shortage record checked October 6, 2026
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509423)
Source record
DIN 02509423: Apo-Sitagliptin Malate/Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509423
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99872
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: active shortage (reported September 30, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02509423
Shortage record checked October 6, 2026
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431
Manufacturer: Apotex Inc.; listing date 2022-12-21
Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509431)
Source record
DIN 02509431: Apo-Sitagliptin Malate/Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509431
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99873
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446
Janumet · DIN 02333872 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: active shortage (reported July 22, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02509431
Shortage record checked October 6, 2026
Apo-Sitagliptin-Metformin · DIN 02435772 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435772
Manufacturer: Apotex Inc.; listing date 2026-03-31
Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435772)
Source record
DIN 02435772: Apo-Sitagliptin-Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435772
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92012
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446
Janumet · DIN 02333856 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02435772
Shortage record checked October 6, 2026
Apo-Sitagliptin-Metformin · DIN 02435780 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435780
Manufacturer: Apotex Inc.; listing date 2026-03-31
Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435780)
Source record
DIN 02435780: Apo-Sitagliptin-Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435780
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92013
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02435780
Shortage record checked October 6, 2026
Apo-Sitagliptin-Metformin · DIN 02435799 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435799
Manufacturer: Apotex Inc.; listing date 2026-03-31
Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435799)
Source record
DIN 02435799: Apo-Sitagliptin-Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id APX
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435799
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92014
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446
Janumet · DIN 02333872 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02435799
Shortage record checked October 6, 2026
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805
Manufacturer: Auro Pharma Inc.; listing date 2025-08-29
Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547805)
Source record
DIN 02547805: Auro-Sitagliptin HCl and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id AUR
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547805
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103673
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446
Janumet · DIN 02333856 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02547805
Shortage record checked October 6, 2026
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813
Manufacturer: Auro Pharma Inc.; listing date 2025-08-29
Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547813)
Source record
DIN 02547813: Auro-Sitagliptin HCl and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id AUR
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103674
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02547813
Shortage record checked October 6, 2026
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821
Manufacturer: Auro Pharma Inc.; listing date 2025-08-29
Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547821)
Source record
DIN 02547821: Auro-Sitagliptin HCl and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id AUR
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547821
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103675
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446
Janumet · DIN 02333872 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02547821
Shortage record checked October 6, 2026
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556189
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-10 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556189)
Source record
DIN 02556189: Jamp Sitagliptin HCl / Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556189
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104488
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446
Janumet · DIN 02333856 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556189
Shortage record checked October 6, 2026
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556197
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-11 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556197)
Source record
DIN 02556197: Jamp Sitagliptin HCl / Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556197
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104489
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556197
Shortage record checked October 6, 2026
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556200
Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29
Health Canada: Marketed since 2025-07-04 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556200)
Source record
DIN 02556200: Jamp Sitagliptin HCl / Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id JPC
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556200
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104490
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446
Janumet · DIN 02333872 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: resolved shortage (ended April 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556200
Shortage record checked October 6, 2026
Janumet · DIN 02333856 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet · DIN 02333856
Manufacturer: Merck Canada Inc.; listing date 2012-02-29
Health Canada: Marketed since 2009-10-08 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333856)
Source record
DIN 02333856: Janumet
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id MEK
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.8496; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333856
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81954
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02333856
Shortage record checked October 6, 2026
Janumet · DIN 02333872 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet · DIN 02333872
Manufacturer: Merck Canada Inc.; listing date 2012-02-29
Health Canada: Marketed since 2009-10-08 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333872)
Source record
DIN 02333872: Janumet
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id MEK
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.8496; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333872
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81956
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: resolved shortage (ended March 17, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02333872
Shortage record checked October 6, 2026
PRZ-Sitagliptin-Metformin · DIN 02552310 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Sitagliptin-Metformin · DIN 02552310
Manufacturer: Pharmaris Canada Inc.; listing date 2026-09-29
Health Canada: Marketed since 2026-06-26 · brand PRZ-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPRZ-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02552310)
Source record
DIN 02552310: PRZ-Sitagliptin-Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id PRZ
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02552310
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104099
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552310
Shortage record checked October 6, 2026
PRZ-Sitagliptin-Metformin · DIN 02552329 · 50 mg & 1000 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PRZ-Sitagliptin-Metformin · DIN 02552329
Manufacturer: Pharmaris Canada Inc.; listing date 2026-09-29
Health Canada: Marketed since 2026-06-30 · brand PRZ-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPRZ-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02552329)
Source record
DIN 02552329: PRZ-Sitagliptin-Metformin
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id PRZ
Source form: Tab; strength: 50mg & 1000mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02552329
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104100
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446
Janumet · DIN 02333872 · $0.4446
Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446
Sitagliptin-Metformin · DIN 02529173 · $0.4446
Sitagliptin/Metformin · DIN 02560461 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02552329
Shortage record checked October 6, 2026
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · 50 mg & 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Reddy-Sitagliptin and Metformin HCl · DIN 02540118
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2025-04-30
Health Canada: Marketed since 2023-10-05 · brand REDDY-SITAGLIPTIN AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReddy-Sitagliptin and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540118)
Source record
DIN 02540118: Reddy-Sitagliptin and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id DRR
Source form: Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540118
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102882
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446
Janumet · DIN 02333856 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446
Sitagliptin-Metformin · DIN 02529157 · $0.4446
Sitagliptin/Metformin · DIN 02560445 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02540118
Shortage record checked October 6, 2026
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · 50 mg & 850 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Reddy-Sitagliptin and Metformin HCl · DIN 02540126
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2025-04-30
Health Canada: Marketed since 2023-10-05 · brand REDDY-SITAGLIPTIN AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordReddy-Sitagliptin and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540126)
Source record
DIN 02540126: Reddy-Sitagliptin and Metformin HCl
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id DRR
Source form: Tab; strength: 50mg & 850mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $0.4446; ministry $0.4446
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540126
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102883
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446
Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446
Janumet · DIN 02333864 · $0.4446
PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446
Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446
Sitagliptin-Metformin · DIN 02529165 · $0.4446
Sitagliptin/Metformin · DIN 02560453 · $0.4446
Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02540126
Shortage record checked October 6, 2026
Other products in the same Health Canada class (A10B, A10BD): coverage varies; not interchangeable
- Dapagliflozin + metformin (Xigduo): general benefit
- Empagliflozin + metformin (Synjardy): general benefit
- Linagliptin + metformin (Jentadueto): general benefit
- Metformin + saxagliptin (Komboglyze): general benefit
- Canagliflozin (Invokana): general benefit
- Dapagliflozin (Forxiga): general benefit
12 more in the class list below
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered
Matched class: 68:20:02 Oral Anti-Diabetic Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN
Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL
68:20:02 Oral Anti-Diabetic Agents
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab
· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab
· 8 products · General benefit · strengths: 100mg, 300mg · Tab
· 22 products · General benefit · strengths: 5mg, 10mg · Tab
· 2 products · General benefit · strengths: 10mg, 25mg · Tab
· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab
· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab
· 1 products · General benefit · strengths: 5mg · Tab
· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab
· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02
and 6 more
Full class listing
Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed)
Same formulary class, not same indication: class membership alone does not establish equivalent uses.